Forest Celexa
Executive Summary
"If Forest terminates Warner-Lambert's co-promotion agreement because of [a Warner-Lambert] merger, under no circumstances would Forest be obligated to make payments until 2004," Forest Chairman Howard Solomon says in a Jan. 27 letter to "The Pink Sheet." Warner-Lambert told a Jan. 19 teleconference that "even if there is that change of control and they exercise their option, there's a period of step down payments that take place through the balance of the six year agreement" (1"The Pink Sheet" Jan. 24, p. 14). Forest and Warner-Lambert are in discussions to end the co-promotion agreement for the antidepressant
You may also be interested in...
Lipitor Holds Up In Merger Dispute; Warner-Lambert, Pfizer Beat Expectations
Warner-Lambert's Lipitor is showing no signs of a negative impact from the distractions caused by the hostile takeover bid launched by Warner's marketing partner Pfizer.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials